A B-lymphocyte binding peptide from BNRF1 induced antibodies inhibiting EBV-invasion of B-lymphocytes

López, Ramsés; Urquiza, Mauricio; Patino, Helena; Suárez, Jorge; Reyes, Claudia; Patarroyo, Manuel A.; Patarroyo, Manuel E.

Ítem

Solo Metadatos

A B-lymphocyte binding peptide from BNRF1 induced antibodies inhibiting EBV-invasion of B-lymphocytes

https://repository.urosario.edu.co/handle/10336/25880
https://doi.org/10.1016/j.biochi.2005.04.009

Autores

López, Ramsés

Urquiza, Mauricio

Patino, Helena

Suárez, Jorge

Reyes, Claudia

Patarroyo, Manuel A.

Patarroyo, Manuel E.

Fecha

2005-11

Editor

Elsevier

Citations

Métricas alternativas

Abstract

Epstein–Barr virus (EBV) infects human target cells mainly through gp350/220-CD21 and gp42-MHCII interactions; however, it has been shown that these interactions are dispensable for EBV-invasion of susceptible cells, suggesting that other viral proteins are involved in this process. It is probable that tegument BNRF1/p140 protein is involved in EBV-invasion of target cells, since anti-p140 antibodies inhibit EBV-infection of B-lymphocytes and there is evidence that part of the protein is located on virus surface. Sixty-six peptides, covering the entire BNRF1/p140 sequence, were synthesised and tested in lymphoblastoid cell line binding assays. Peptides 11465 and 11521 bound with high affinity to Raji, Ramos and P3HR-1 cells but not to erythrocytes, showing cell-binding behaviour similar to EBV. These two peptides induced antibodies recognising live EBV-infected cells. Interestingly, peptide-11521 (YVLQNAHQIACHFHSNGTDA) or antibodies induced by this peptide inhibited EBV-binding to B-lymphocytes, suggesting that this p140-region could be involved in EBV and B-lymphocyte interaction.